Kineta Resumes Enrollment Of Anti-VISTA Antibody Trial

 
• By Joseph Haas
  
Immune checkpoint inhibitor
Kineta resumes enrolling a trial for what it hopes will be a novel class of checkpoint inhibitors • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D